A comparative effectiveness study involving over 79,000 acute ischemic stroke patients found similar short-term efficacy and safety between tenecteplase and alteplase for thrombolytic therapy.

Patients treated with tenecteplase showed comparable functional independence and symptomatic intracranial hemorrhage rates as those treated with alteplase. Tenecteplase emerged as a reasonable alternative, particularly for large vessel occlusion patients not eligible for endovascular thrombectomy, due to simpler administration and potential workflow efficiency improvements. The study suggests the need for future research on differences across stroke subtypes and patient populations.

Source: JAMA Network Open